United States 2026 · Every advertiser
Biosplice Therapeutics
This page ran 12 paid political ads on Facebook and Instagram between 29 August 2026 and 11 October 2026. Meta reports $2.4–4K of spend, which makes it the 8,262nd largest advertiser of the 24,034 pages in our data. Advertiser type: Unidentified. Most of its spend took no side. Race: No specific race.
Data from the Meta Ad Library, pulled 4 November 2026. Election on 3 November 2026. · Every ad of this page in Meta’s Ad Library ↗
12
ads
$3.2K
reported spend, range $2.4–4K
0.0%
of spend on federal races
$50
median spend per ad
Spend by week the ad started
Tone
Share of the 12 ads with text that our model classified. Attack ads name an opponent.
Topics
Spend by race: No specific race 100%.
Spend by ad language: English 100%.
The costliest ads
The highest-spend ad of each distinct text, as it ran.
Sorry to bother you, but if you live with knee OA and knee pain, you’re going to want to sign this. It takes about 60 seconds. We’ll prepare the letter. You add your information and send it to your representative. Make your voice heard ↓
15 September 2026 · Biosplice Therapeutics · $1.5–2K · 25K+ impressions · Informational · Ad Library
Lorecivivint (LOR) is the knee OA drug now under FDA review. Here's what Phase 3 trials showed vs placebo: ✅ Less pain and better function at 12 months ✅ Less joint space loss over 3 years ✅ Side effect rates similar to placebo If the FDA approves it, it could be available as soon as next year. Congress needs to hear that knee OA patients want this reviewed quickly. Send a letter to your Representative. It takes 60 seconds. 👇 Lorecivivint is investigational and not FDA-approved.
11 October 2026 · Biosplice Therapeutics · $100 – $199 · 2K+ impressions · Informational · Ad Library
Knee osteoarthritis isn't just pain — it's the joint itself breaking down. Yet almost everything available today is aimed at the pain. Tell your Representative that osteoarthritis research deserves priority. We'll prepare the letter — just add your information.
10 September 2026 · Biosplice Therapeutics · $100 – $199 · 2K+ impressions · Informational · Ad Library
Knee osteoarthritis isn't just "wear and tear," and it isn't an inevitable part of getting older. It's a progressive structural disease of the joint. Every available treatment manages pain. None has been shown to repair cartilage or stop structural damage from progressing. Congress decides what research gets funded and what the FDA is directed to prioritize. Your Representative needs to hear that osteoarthritis needs real treatment options — not just better painkillers. Message your Represent
29 August 2026 · Biosplice Therapeutics · $100 – $199 · 15K+ impressions · Informational · Ad Library
Knee osteoarthritis affects millions of Americans, yet many people have never shared their experience with their Representative. A letter has already been prepared. If you choose to participate, you can add your name and briefly share your experience. It takes about 60 seconds. Share your experience
15 September 2026 · Biosplice Therapeutics · $0 – $99 · 100+ impressions · Informational · Ad Library
Knee osteoarthritis affects millions of Americans — and today's options mostly manage the pain. We'll prepare the letter. Add your information and make your voice heard for better osteoarthritis treatment options.
10 September 2026 · Biosplice Therapeutics · $0 – $99 · 100+ impressions · Informational · Ad Library
Figures cover domestic political ads paid in dollars, from 4 May 2026. Spend is the sum of Meta’s range midpoints; impressions above one million are reported as “1M+”, so impression figures are floors. Each ad counts in the week its delivery started, with its lifetime spend at our last pull; ads still running before the vote are counted as of 31 October 2026.
Back to the United States report, both parties and every candidate or every advertiser.